In the late referral group, 15 patients required commencement of

In the late referral group, 15 patients required commencement of dialysis via a temporary

central venous access, pulmonary oedema was present in 13 patients and malignant hypertension was present in three patients. The later referral group was characterized by more severe biochemical and haematological markers of uraemia such as higher serum creatinine and phosphate concentrations and lower creatinine clearance, serum bicarbonate, calcium and haemoglobin. Systolic and diastolic blood pressures were also significantly higher in the late referral group. The duration of hospitalization (33.2 ± 13.1 days vs 5.7 ± 1.1 days, P < 0.001) and the cost of hospitalization were significantly higher in the late referral group. Ellis et al. in 1998 reported a retrospective CP673451 review of all patients who developed ESKD and who were accepted for renal replacement therapy (RRT) at Kings College, London over a 2-year period from 1 January 1996 to 31 December 1997.33 Sixty-four patients were regarded as late referral (<12 weeks prior to commencing RRT) and 134 patients were classified as early referral (>12 weeks prior to starting RRT). In the late referral group, there was objective evidence of renal disease for at least

selleck 8 weeks in 50% of patients and 22% of patients had evidence of renal disease for at least 1 year prior to the time of referral. Suboptimal management of CKD prior to referral to the nephrology service was common. Only 33% of diabetic patients were treated with an angiotensin-converting enzyme inhibitor and 49% of patients with CKD and hypertension had inadequate control of blood pressure at the time of referral to the nephrology service. The length of hospitalization was significantly longer in the late referral group (25 vs 9.7 days, P < 0.001). However, there was no difference in mortality between the early and late referral groups (12-month survival: Miconazole 60.5% vs 72.5%). Khan et al. in 1995 reported factors associated with early mortality on dialysis in a retrospective,

case–control study of patients being dialysed at a single centre in Aberdeen (UK) between 1 January 1971 and 6 January 1993.34 Forty-two patients who died within 90 days of the commencement of haemodialysis were compared with age- and sex-matched patients who survived longer than 90 days. In the early mortality group, there were a higher proportion of patients who required urgent dialysis (79% vs 21%, P < 0.05) and there was a shorter period of predialysis management (1.1 vs 10.6 months, P < 0.0001). A greater prevalence of arteriolosclerosis, comorbid illness and smoking and a lower mean serum albumin (31.4 vs 37.1 g/L, P < 0.006) were also identified in the early mortality group. A similar experience was reported by Innes et al. in a retrospective analysis of 44 patients who died within 1 year of starting dialysis compared to 44 age- and sex-matched patients who survived more than 1 year.

Posted in Antibody | Leave a comment

Renal transplantation for APS patients with ESKD is associated wi

Renal transplantation for APS patients with ESKD is associated with increased risk of systemic or allograft thrombosis or TMA.[22, 23] Here we present a transplant recipient with SLE and APS who developed acute allograft dysfunction associated with TMA, despite perioperative anticoagulation. A 26-year-old non-smoking, nulliparous female presented with three

weeks of wrist and finger pain, rash involving the face and chest, mouth ulcers, fevers, weight loss and lethargy. Blood pressure was 130/70 mmHg PF-01367338 cost and dipstick urinalysis revealed protein (2+) and blood (3+). Urine microscopy showed dysmorphic erythrocytes (470 × 106/L) and leukocytes (150 × 106/L), with no bacterial growth, and 24-hour urinary protein excretion was 2.1 g/day. Full blood count, serum electrolytes and liver function tests were unremarkable. Immunology

studies (Table 2) revealed a positive antinuclear antibody (ANA 1/640 titre in a homogeneous pattern) and anti-double-stranded DNA (dsDNA). Serum complement C3 and C4 were low. LA was positive with a prolonged activated partial thromboplastin time (APTT) that failed to correct with normal serum and confirmation of phospholipid dependence through platelet neutralization. aCL antibodies were strongly positive (anti-β2-GP1 antibodies were not tested). Treatment for SLE was commenced with oral prednisolone and hydroxychloroquine. Subsequently the patient presented with a lower limb DVT, which combined with the persistently positive LA and high-titre aCL antibodies led to a diagnosis of APS. Anticoagulation was begun with low molecular weight Proteasome inhibitor heparin (LMWH) followed by warfarin, later replaced by aspirin. The patient remained well without medical review for a number of years before returning with a systemic flare of

SLE and renal involvement. Renal biopsy at this time revealed diffuse proliferative lupus nephritis (WHO class IV-g/a). Administration of high-dose steroids, mycophenolate mofetil, and rituximab was followed by a fall in the dsDNA titre and normalization of serum complement levels, but LA and aCL antibodies remained positive. Anaemia (haemoglobin 95 g/L) and thrombocytopenia (platelet count 65 × 109/L) this website were present without red cell fragmentation. Renal function deteriorated leading to dialysis dependence, and a further biopsy showed quiescent lupus nephritis with superimposed TMA. Glomeruli were variably haemorrhagic or ischaemic, many showing fibrin thrombi at the vascular pole and red cell fragments in capillary lumina. Electron microscopy revealed markedly swollen endothelial cells and abundant subendothelial flocculant material. Assays for reduced ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 domains, number 13) activity, anti-ADAMTS13 autoantibodies, complement regulatory gene mutations and anti-factor H autoantibodies were not performed.

Posted in Antibody | Leave a comment

DENV isolates passed serially from brain to brain led to increase

DENV isolates passed serially from brain to brain led to increased neurovirulence and neurotropism in mice[44] and a clear attenuation in human volunteers.[45] However, viral encephalitis is not a major clinical symptom in human dengue disease, as nervous system involvement in DENV infections is

rare and few cases are reported.[46] The IFN system is critical to the host antiviral response, which led to the use of AG129 mice, which are type I and II IFN-R-deficient 129 mice, immune deficient and highly susceptible.[47] Intraperitoneal infection with the mouse-adapted neurotropic DENV-2 strain, New Guinea C, led to 100% lethality in AG129 mice, all of them presenting paralysis.[48] The neuroinflammatory changes led to alterations in motor behaviour and muscle tone and strength in DENV-3-infected mice. The neuroinflammatory process was marked by up-regulation of the chemokines LY2109761 CCL2, CCL5, CXCL1 and CXCL2, and of the cytokines TNF-α and IFN-γ, which occurs in parallel with increased leucocyte rolling and adhesion in meningeal vessels and infiltration of immune cells into the brain.[49] In summary, even if these models were used to study antiviral compounds or behaviour, the major limitation involving immune-compromised mice is that paralysis is not a major clinical observation in DENV infection. Initial tropism studies using the

AG129 (IFN type I and II receptor-deficient) model demonstrated that clinical isolates from all four DENV serotypes replicate PD0325901 purchase efficiently in spleen, lymph node, bone marrow and muscle.[50] Negative-strand

viral RNA was detected in dendritic cells and macrophages of the lymph node and spleen.[50] To develop an experimental model where viral encephalitis was not the major clinical observation, Shresta et al.[47] infected AG129 mice intravenously with the DENV-2 strain PL046. Infected AG129 mice succumbed to DENV infection, almost presenting increased levels of TNF-α and vascular leakage syndrome. AG129 mice are able develop cross-reactive and long-lasting antibody responses to DENV.[51] Sequential DENV infection in AG129 mice results in decreased viral load of the second serotype and full protection against lethal infection. AG129 and other mouse strains have been used to study ADE by passive transfer of anti-DENV monoclonal antibodies, cross-reactive immune serum, or diluted homotypic serum before infection.[52, 53] Mortality was associated with vascular leakage syndrome, high levels of TNF-α and thrombocytopenia, similar to the clinical findings observed in DHF/DSS in humans. No memory response was observed in mice receiving passive transfer of serum or antibody. Hence, models of sequential DENV infection may be useful to study ADE in the presence of a cellular memory immune response.

Posted in Antibody | Leave a comment

We consistently observed constitutive expression of TLT-2 in LN C

We consistently observed constitutive expression of TLT-2 in LN CD8+ T cells from naive mice, and its expression was comparable in RLN CD8+ T cells from tumour-bearing AZD2014 mice. Here, we examined TLT-2 expression in TIL for the first time. We found a marked lymphocyte infiltration within the B7-H3/SCCVII tumour mass, indicating active anti-tumour immune responses in the B7-H3+ tumour sites. Surprisingly, the majority of CD8+ TIL in the B7-H3/SCCVII-inoculated mice

lost TLT-2 expression, and the cells expressing activation marker down-regulated TLT-2 expression. These findings suggest that activation signals to CD8+ T cells induce down-regulation of TLT-2. Although we tried to detect TLT-2 expression by immunofluorescence histostaining, TLT-2 expression was undetectable so we could not examine the distribution of TLT-2+ versus TLT-2− CD8 TIL in the tissues. We also found that TGF-β, which is often secreted from solid tumour cells like squamous cell carcinomas or tumour-associated cells, down-regulated TLT-2 expression. It is therefore possible that some tumour-related environmental factor(s) may have caused

TLT-2 down-regulation. TLT-2 down-regulation occurred at the local tumour sites and this may have contributed to the limited efficacy of B7-H3-transduced tumours. Our results from the TLT-2-transduced CD8+ T-cell study suggest that the TLT-2 expression level is more critical than that of B7-H3 to deciding whether there is a contribution of the B7-H3–TLT-2 pathway. Over-expression of B7-H3 is no longer required Selleckchem Ku 0059436 when sufficient TLT-2 expression is provided on the surface of CD8+ T cells (Fig. 6d). In

contrast to broad and abundant B7-H3 expression, TLT-2 expression levels in T cells are tightly regulated. Additional approaches for preventing TLT-2 down-regulation or enhancing TLT-2 expression at tumour sites may be needed. We performed experiments to block the B7-H3–TLT-2 pathway, using anti-B7-H3 and anti-TLT-2 mAbs, to confirm the functional contribution of B7-H3 and TLT-2 in B7-H3-introduced tumour-mediated immunity. Unfortunately, Acetophenone there was no effect on the tumour regression induced by B7-H3-introduced tumours that expressed high levels of B7-H3. Interestingly, growth of the parental tumour, which expressed endogenously low levels of B7-H3, was accelerated by treatment with either anti-B7-H3 or anti-TLT-2 mAb. This suggests the immunoenhancing effects of the B7-H3–TLT-2 pathway in tumour immunity against parental tumours. We have previously attempted and failed to reverse the enhanced responses induced by B7-H3- or TLT-2-transduced cells using the same anti-B7-H3 and TLT-2 mAbs in vitro, although these mAbs could inhibit B7-H3 immunoglobulin binding, assessed by flow cytometry, and the functional endogenous TLT-2 and B7-H3 interaction in contact hypersensitivity in vivo.28 The low affinity of our blocking mAbs may explain the failure.

Posted in Antibody | Leave a comment

The transcription factor interferon regulatory factor 5 (IRF5) is

The transcription factor interferon regulatory factor 5 (IRF5) is one SLE susceptibility gene recently identified [[6]]. Multiple studies have confirmed the presence of IRF5 genetic variants that show strong association with increased risk of developing SLE [[6-8]]. Association has been convincingly replicated in SLE patients from multiple populations and distinct IRF5 haplotypes that Gefitinib concentration confer either susceptibility to (risk), or protection from, SLE in persons of varying ethnic ancestry have been identified [[6-11]]. A potential biologic role for IRF5 in human SLE pathogenesis has been supported

by the fact that elevated IRF5 mRNA levels are associated with specific IRF5 risk variants [[7, 8, 12, 13]]. Subsequently, we demonstrated that IRF5 mRNA and protein abundance were significantly elevated in primary blood cells of SLE patients, as compared to healthy donors, independent of IRF5 risk variants;

however, a correlation between IRF5 expression and the IRF5 risk haplotype was obtained [[14]]. These data support a more global role for PKC412 in vitro IRF5 in SLE pathogenesis that is both genotype dependent and genotype independent. IRF5 regulates type I IFN expression in response to a variety of pathogenic stimuli and is a critical mediator of MyD88-dependent Toll-like receptor (TLR) signaling [[15-18]]. Proinflammatory cytokines elevated in the serum of lupus patients, that is IFN-α, interleukin (IL)-6, IL-12, and tumor necrosis factor (TNF)-α, are regulated by IRF5 [[16]]. In mice, the production of IFN-α/β and IL-6 in response to sera or IgG–RNA immune complexes (IC) from lupus

patients was shown to be Tlr7, Irf5, and Irf7 dependent [[19]]. These data support aminophylline the conventional wisdom that elevated IRF5 expression in SLE patients may drive disease development by causing aberrant production of type I IFN through TLR7 and/or TLR9 signaling that is activated by IC [[20, 21]]. Correlative data supporting this has been obtained in SLE patients demonstrating association of an IRF5 risk haplotype with IFN-α activity that was dependent on autoantibodies [[22]]. Recently, it was demonstrated that FcRIIb−/− and FcRIIb−/−Yaa mice lacking Irf5 had significantly decreased autoantibody production, limited glomerular IgG deposition, and enhanced survival [[23]]. Little mechanistic insight was provided for the protective Irf5−/− phenotype. A subsequent study demonstrated that IRF5 regulates transcription of the γ2a locus resulting in decreased autoantibody production [[24]]. Surprisingly, neither study directly addressed whether loss of Irf5 affected type I IFN expression [[23, 24]]. We hypothesized that loss of Irf5 would alter multiple aspects of autoimmunity due to its regulation of the pleiotropic cytokine type I IFN and other proinflammatory cytokines [[15-18]].

Posted in Antibody | Leave a comment

43 The question of whether or not Tregs are numerically deficient

43 The question of whether or not Tregs are numerically deficient SAHA HDAC in vivo in IBD therefore warrants re-investigation using more comprehensive panels of cell surface markers and cytokines. There is also little evidence to support the possibility that intestinal Tregs are dysfunctional in IBD because Tregs isolated from the intestinal mucosa of patients with IBD

are suppressive in vitro.38,40 On the other hand, there is evidence that Tregs from inflamed colonic tissue undergo apoptosis more readily than Tregs found in non-inflamed tissue, possibly rendering the Tregs less effective.44 It is important to note, however, that the functional Treg assays in these studies selleck chemical were performed using non-specific antigen stimulation in conditions lacking many of the cytokines that would be found in the inflamed intestinal environment. Moreover, to date only suppression of T-cell responses has been examined, and the possibility that Tregs from IBD patients may lack the ability to suppress other cell types, such as antigen-presenting cells or B cells, has yet

to be investigated. Hence whether or not the inflamed mucosal environment renders Tregs dysfunctional remains unknown, as does what would happen to Tregs – i.e. would they remain suppressive – if they were administered as a cellular therapy. If the inflamed intestine has a normal number of Tregs which, at least in vitro, appear to Bumetanide be functional, then why are they unable to block inflammation? In other autoimmune diseases, including type 1 diabetes and multiple sclerosis, there is extensive evidence suggesting that the defect in immune regulation lies within the effector cell/inflammatory environment and not the Tregs themselves.45 In IBD the question of whether effector T cells show abnormal resistance to suppression in IBD has not yet been comprehensively studied but there are some studies suggesting that this may be the case. In colitic mice and humans effector T cells can be resistant to Tregs if they become insensitive to

TGF-β-mediated suppression.46,47 How the inflamed intestinal environment affects the result of Treg activity is a major outstanding question: addition of more Treg cells to a setting that is resistant to their effects may be futile. All Tregs are ultimately defined by their ability to suppress immune responses; however, nTregs, iTregs and Tr1 cells may differ in the suppressive mechanisms they employ and so have distinct advantages as therapies in mucosal diseases. nTregs are the best-studied type of Tregs and have already been successfully used in humans,12–15 but as these cells are primarily thought to be specific for self-antigens48 they may lack potency towards immune responses directed to the foreign antigens present in the gut.

Posted in Antibody | Leave a comment

[2] In some areas of the sheep placenta, called placentomes, ther

[2] In some areas of the sheep placenta, called placentomes, there is aggressive interdigitation between trophoblast villi on the fetal side (cotyledon) and the

uterus on the maternal side (caruncle), and at points the epithelia form a common syncytium allowing for more efficiency of gas and nutrient exchange. Pigs have a similar but more diffuse placental structure than sheep with less aggressive interdigitation.[2, 17] The human/primate uterus is a single muscular organ different structurally from the two-horned uterus of rodents (for mice see Margaret J Cook’s Selleck INK-128 book at, pigs,[18] rabbits,[16] or sheep.[19] While the electro-mechanics of the human/primate uterus may be fundamentally different from that seen in other species,[20, 21] the uteri of rodents,[22] rabbits[23] sheep,[24] and pigs[18] respond to oxytocin, suggesting a common expression

of the receptor, and most have been used to study the mechanisms underlying uterine contractility in vitro. In addition to hormones such as estrogen (discussed elsewhere), progesterone is a key hormone of pregnancy that appears to be differentially regulated in humans and animals.[25] The particulars of the responsiveness to this hormone and its interaction with estrogen in successful pregnancy remain Copanlisib nmr a topic of intense investigation. In humans, the corpus luteum is the major site of progesterone expression with help from chorionic

gonadotropin released by the early conceptus.[26] Blockade of progesterone during this time causes pregnancy loss.[26] Major production of progesterone switches to the placenta by 5–6 weeks’ gestation. Maternal serum levels of progesterone raise post-conceptionally and continue to elevate beyond parturition.[25, 27] However, progesterone has been given with variable success to treat women with recurrent miscarriage[28] and antiprogesterone given late in pregnancy can cause cervical ripening and delivery in some women[29] suggesting a complex biology. Human fetal membranes can produce[30] 4��8C and metabolize progesterone,[31] and locally produced progesterone metabolites may be important in uterine quiescence and activation.[32] The human uterus can produce an inhibitory progesterone receptor which increases before parturition.[33] Finally, progesterone receptor regulation at multiple levels in the cytoplasm and the nucleus may regulate functional progesterone activity leading to parturition.[34] Progesterone’s regulation during pregnancy in related non-human primates is similar to human pregnancy in several respects including dependence on early production of progesterone by the corpus luteum[35] that early pregnancy can be interrupted by antiprogestins[36] and that there is not systemic withdrawal before parturition.

Posted in Antibody | Leave a comment

Background —

Background.— check details The prevalence of sleep disorders in chronic headache has been seldom investigated, although from the earliest description chronic headache has been associated with sleep disturbances. On the contrary, mood disorders are commonly associated with both sleep disturbances and chronic headache – each of which are, in turn,

core features of mood disorders. Therefore, it may be important to discriminate between sleep problems that can be attributed to a comorbid psychiatric disorder, and those specifically associated with headache. Only a few studies investigating the association of chronic headache with sleep difficulties have also taken into account to consider the possible role of anxiety and depression. Patients and Methods.— A total of 105 consecutive patients with daily or nearly daily headache and

102 patients with episodic headache, matched by age, sex, and type of headache at onset, underwent a structured direct interview about their sleep habits and psychiatric diseases. Results.— In Decitabine molecular weight total, 80 out of 105 patients with chronic headache received a diagnosis of medication overuse headache, 21 patients were classified as chronic migraine and 4 as chronic tension-type headache without drug overuse. Patients.— Patients with chronic headache showed a high prevalence of insomnia, daytime sleepiness, and snoring with respect to controls (67.7% vs 39.2%, 36.2% vs 23.5%, and 48.6% vs 37.2%, respectively). Forty-five patients with chronic headache (42.9%) had psychiatric comorbidity (anxiety and/or depressive disorders), vs 27 episodic headache patients (26.5%). Multivariate Oxalosuccinic acid analysis disclosed that low educational level, lower mean age at headache onset, and insomnia are independently associated with chronic headache. Conclusions.— Patients with chronic headache had a high prevalence of sleep complaints. Insomnia may thus represent an independent risk factor

for headache chronification. Recognition of sleep disorders, alone or in association with depression or anxiety, may be useful in episodic headache patients to prevent chronification. “
“(Headache 2011;51:8-20) Introduction.— Several studies have reported that migraine headaches are more common in patients with allergic rhinitis and that immunotherapy decreases the frequency of headache in atopic headache sufferers. Objective.— To determine if the degree of allergic sensitization and the administration of immunotherapy are associated with the prevalence, frequency, and disability of migraine headache in patients with allergic rhinitis. Methods.— Consecutive patients between the ages of 18-65 presenting to an allergy practice that received a diagnosis of an allergic rhinitis subtype (eg, allergic or mixed rhinitis) were enrolled in this study. All participants underwent allergy testing as well as a structured verbal headache diagnostic interview to ascertain the clinical characteristics of each headache type.

Posted in Antibody | Leave a comment

L selectin was blocked and hepatocellular damage after IRI was as

L selectin was blocked and hepatocellular damage after IRI was assessed to mechanistically define the role of the adhesion molecule. Results: Mice fed a HFD diet showed significant increase in body weight (42±1.2, vs. 24.6±0.6 grams; p<0.0001) and presence of hepatic steatosis by ORO stain. Splenocytes from HFD mice undergoing IRI demonstrated significant increase in CD4+ T cell activation markers, such as PD1

(p<0.0009), CD69(p<0.01), and CD62L(p<0.001), in addition to higher Venetoclax levels of serum ALT and significant increase in hepatocellular necrosis. The T cell proliferation marker Ki67 (p<0.0089), was significantly higher in HFD IRI as compared to lean IRI. Expression levels of L-selectin (p<0.03) but not P or E-selectin were elevated in HFD IRI. Increased cytokines such as IFNγ, IL-1a, IL-10, IL-6 and IL-17, suggested a pro-inflammatory milieu in HFD IRI. Blockade of L-selectin, lead to a significant attenuation of hepatocellular injury. Conclusion: A steatotic liver undergoing IRI is associated with elevation of adhesion molecule L-se-lectin along with activation and proliferation of CD4+ T cells, and a pro-inflammatory

cytokine milieu. Blocking the adhesion molecule L-selectin leads to mitigation of hepatocellular injury, thus offering an important and clinically relevant therapeutic intervention in the increasingly prevalent clinical condition of IRI of fatty liver U0126 molecular weight disease. Disclosures: The following people have nothing to disclose: Vasantha L. Kolachala, Abramowsky Carlos, Ming Shen, Alayna Feng, Allan D. Kirk,

Nitika A. Gupta “
“From the mid-1950s, it was observed that liver injury by a variety of toxins greatly sensitized the host to the effects of administered lipopolysaccharide. In the nutritional cirrhosis of choline deficiency, and in acute toxic injury as well, the need for the presence of enteric endotoxin was demonstrated. The universality of this association was striking for almost all agents associated Buspirone HCl with liver injury. In addition, the presence of endotoxemia in human liver disease was documented in the 1970s, when the hypothesis was first proposed, and correlated with the severity of the disease. Despite imposing evidence of the critical role of enteric endotoxin in liver injury, it did not excite much interest in investigators until the 1980s. With the ability to study effects of alcohol in newer delivery systems, and an increased understanding of the role of Kupffer cells in the process, the original hypothesis has been accepted. This historical review details the progress of this novel concept of disease initiation and suggests future directions to bring potential therapies to the bedside. (HEPATOLOGY 2010.) Continuing work over the past several decades has further solidified the importance of intestinal endotoxins as critical cofactors in toxic liver injury by a number of agents.

Posted in Antibody | Leave a comment

Reassuring results of a low rate of de novo inhibitors in PTPs wh

Reassuring results of a low rate of de novo inhibitors in PTPs who switched from pd-FVIII to rFVIII were shown in prospective premarketing studies carried out with these new products [45-50]. Subsequently, selleck inhibitor national product switches have provided important pieces of evidence. Two surveillance studies were carried out in Canada during the population switch from pd-FVIII to rFVIII and then from first to second generation rFVIII and neither of these studies showed an increase in inhibitor incidence [51, 52]. A retrospective

study performed in Ireland after a national tender with consequent en masse switch to a third generation full-length rFVIII did not detect changes in the rate of de novo inhibitor formation [53]. In the UK a national tender was floated in 2009–2010 and it required half of patients using rFVIII to change

rFVIII brands [54]. Inhibitor testing was performed in all patients prior to the switching date and 6-monthly thereafter. Overall 1217 patients with severe haemophilia A and no inhibitor history were analysed (535 switched and 682 did not). Almost all patients who switched changed to B-domainless rFVIII. The inhibitor incidence was not significantly different from that observed during the previous two decades [54]. All these studies indicate that switching is not associated with an increased risk of de novo inhibitor formation. However, due to the very low inhibitor incidence in PTPs, all studies were learn more underpowered. Meta-analyses of PTPs studies were also performed to gain further insight into the available evidence. This methodology was applied to compare the inhibitor risk in PTPs receiving full-length rFVIII with that of patients given B-domainless rFVIII [55]. Unexpectedly, a sevenfold to 10-fold higher inhibitor incidence was found Amylase in recipients of B-domainless FVIII [55]. These results were not confirmed in a subsequent systematic review

and meta-analysis adopting strict criteria for study selection [56]. In conclusion, prospective, controlled surveillance programmes on switching and not switching patients are still required to provide robust evidence concerning the inhibitor risk related to product switching. In this respect, inhibitor testing before and after the switch as well as testing of not switching patients is a crucial element to establish the correlation with the new treatment. The availability over time of newer therapeutic molecules and the variable market accessibility of different products often entail switching; in this light, patient information on evidences concerning potential risks and benefits associated with product switching is mandatory and should be part of our routine practice. Furthermore, physicians should discuss with patients and their caregivers the different therapeutic approaches and the available product options before the possible need for considering product switch.

Posted in Antibody | Leave a comment